Integragen (ALINT.PA) Azione Prezzo
Integragen Prezzo
Il fatturato è cresciuto a un tasso composto del 4,3% annuo negli ultimi 18 anni, raggiungendo 5,02 Mio. EUR. Il margine netto di Integragen si attesta al -53,1%, in calo rispetto al 0,1% di alcuni anni fa.
Integragen Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Integragen Azione e analisi azionaria
Domande frequenti sull'azione Integragen
Integragen SA is a leading company specializing in innovative genomic services and molecular diagnostics. Their business model revolves around providing personalized healthcare solutions through cutting-edge genetic analysis and bioinformatics. By leveraging their expertise in advanced sequencing technologies, Integragen offers accurate and reliable genetic testing services to improve patient care. They prioritize collaboration with healthcare professionals and researchers to deliver customized genomic insights for a range of applications, including cancer diagnostics, rare diseases, and pharmacogenomics. Integragen SA's commitment to leveraging genomics for better health outcomes makes them an esteemed player in the field of precision medicine.
Integragen SA is primarily active in the field of genetic sequencing and molecular diagnostics for cancer and autism. This French biotechnology company specializes in providing innovative solutions and services to healthcare professionals and researchers. With its cutting-edge technology and expertise in genomics, Integragen SA aims to improve patient care and advance scientific discoveries in these critical areas.
The main competitors of Integragen SA in the market include Genomic Health Inc., Foundation Medicine Inc., and Veracyte Inc.
Integragen SA, founded in 2000, is a leading biotechnology company specializing in genomic solutions for personalized medicine. Headquartered in France, the company focuses on the development and implementation of advanced genomic testing methods. With a strong background in genetic research, Integragen SA offers comprehensive molecular diagnostics and innovative solutions for disease management. Its expertise lies in genetic sequencing, bioinformatics, and data analysis, enabling it to provide personalized insights into various medical conditions. Integragen SA's commitment to revolutionizing healthcare through genomics has established it as a trusted partner in the advancement of personalized medicine.
Integragen SA, a leading company in the field of genomics, has achieved numerous significant milestones. One notable achievement is their development of innovative genomic solutions, catering to the needs of both academic researchers and healthcare professionals. By leveraging their advanced technology and expertise, Integragen SA has successfully provided high-quality genomic sequencing and analysis services to various institutions and organizations. Additionally, the company has made significant contributions to the development of personalized medicine, allowing for better understanding and treatment of complex diseases. Integragen SA's commitment to excellence and continual innovation has positioned them as a prominent player in the genomics industry, driving advancements in healthcare and research.
Integragen SA is primarily present in France, the United States, and Belgium.
Integragen SA represents strong values and a unique corporate philosophy. With a focus on innovation and scientific excellence, Integragen SA constantly strives to provide cutting-edge genetic solutions to its clients. The company's commitment to quality and precision enables them to offer personalized healthcare and diagnostic services, catering to the individual needs of each patient. Integragen SA prioritizes ethical practices and values collaboration, fostering partnerships with leading research institutions and healthcare providers. By harnessing the power of genomics, Integragen SA aims to improve patient outcomes and contribute to the advancement of precision medicine.
9 analisti valutano attualmente l’azione Integragen: 8 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Integragen ricavi pari a 6,50 Mio. EUR e un utile per azione di -0,21 EUR.
L’azione Integragen (ALINT.PA) è quotata su 2 borse, tra cui: Paris (ALINT.PA).
Integragen SA is a company specialized in the development and sale of genetic tests and data analysis. The company was founded in 2000 and is headquartered in Evry, France. Its core business is DNA sequencing and analysis, conducting genome studies, pharmacogenomics, biomarker development, precise diagnostics, and personalized medicine. Integragen has three core divisions: Biopharmaceuticals, Medical Genomics, and Research Support. It offers services to support biotech and pharmaceutical companies in developing personalized medicines, assists healthcare professionals in identifying genetic changes in patients, and provides comprehensive genomics services for genetic research. The company also offers various genetic tests for cancer prevention and diagnosis, assessing the risk of cardiovascular diseases, and grouping metabolism processes. Integragen has a wide network of partners in the biotech and pharmaceutical industry, as well as academia, and aims to expand its business through strategic partnerships and acquisitions. In summary, Integragen is a leading company in the genomics industry with a wide range of services and products, focusing on personalized medicine and genetic research to drive growth in the coming years.
Il attesa fatturato di Integragen ammonta a 6,50 Mio. EUR. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Integragen ammonta a -1,48 Mio. EUR. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Integragen è attualmente -0,35. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Integragen.
Il rapporto prezzo/fatturato (P/S) di Integragen è attualmente 0,08. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Integragen.
Il Quality Score AlleAktien per Integragen è 4/10.
L'ISIN di Integragen è FR0010908723. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Integragen è A1J1JV. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Integragen è ALINT.PA. Con questo simbolo di borsa vengono negoziate le azioni Integragen in borsa.
Azione Integragen
Gruppo di pari di Integragen
Integragen Ticker
Integragen FIGI
Altre metriche e analisi di Integragen in Deep Dive.
La nostra analisi azionaria dell'azione Integragen include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Integragen. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: